Program
casdatifan
Also written as “Casdatifan” and “AB521”.
Its studies are mostly in Carcinoma, Renal Cell · Clear-cell metastatic renal cell carcinoma, led by 3 companies.
Drug pageCasdatifan: every studyAll 10 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Arcus Biosciences | 73 open or running | phase 3since Jun 2, 2025 | Nov 2, 2021 | May 2027phase 1 · NCT07751250 |
| AstraZenecaits history only | 11 open or running | phase 1since May 23, 2025 | May 23, 2025 | Jan 29, 2027phase 1 · NCT07000149 |
| Exelixisits history only | 10 open or running | phase 1since Dec 19, 2023 | Dec 19, 2023 | none ahead |
Also a collaborator on its studies: Summit Therapeutics, LG Chem and Otsuka.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Arcus Biosciences only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Nov 2, 2021First study: phase 1 study in Healthy ParticipantsFirst studyNCT05117554 · 70 enrolled · Netherlands
- Sep 7, 2022Phase 1 study in Carcinoma, Renal CellNCT05536141 · 512 planned · United States, Australia, South Korea and more
- Aug 14, 2023Phase 1 study in Healthy ParticipantsNCT05999513 · 24 enrolled · United States
- Aug 11, 2024Named casdatifanINNProposed as its International Nonproprietary Name in WHO's List 131 · before, AB521
- Mar 27, 2025Phase 1 study in Healthy ParticipantsNCT06919991 · 14 enrolled · United States
- Jun 2, 2025Phase 3 study in Clear-cell metastatic renal cell carcinomaNCT07011719 · 720 planned · United States, Argentina, Australia and more
- Jun 8, 2026Phase 1 study in Healthy ParticipantsNCT07641881 · 24 enrolled · United States
- Aug 3, 2026Phase 1 study in Healthy ParticipantsNCT07751250 · 16 planned · United States
Ahead
- May 2027Primary completion: phase 1 study in Healthy ParticipantsNCT07751250
- Apr 2028Primary completion: phase 3 study in Clear-cell metastatic renal cell carcinomaNCT07011719
- Mar 2029Primary completion: phase 1 study in Carcinoma, Renal CellNCT05536141
TargetBeta
“This is a single-institution, pilot study of oral casdatifan, a selective HIF-2α inhibitor, in patients with metastatic clear cell renal cell carcinoma refractory to prior IO- and VEGF-based therapies.”study text, by rule · the study
Other programs on EPAS1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| belzutifanrule | Merck | phase 3 | 24 |
Studies
All 7 Arcus Biosciences leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07751250Healthy Participants · United States | 1 | Recruiting | May 2027 | 16 |
| NCT07641881Healthy Participants · United States | 1 | Completed | Jul 3, 2026 | 24 |
| NCT07011719Clear-cell metastatic renal cell carcinoma · United States, Argentina, Australia and more | 3 | Recruiting | Apr 2028 | 720 |
| NCT06919991Healthy Participants · United States | 1 | Completed | Oct 18, 2025 | 14 |
| NCT05999513Healthy Participants · United States | 1 | Completed | Oct 31, 2023 | 24 |
| NCT05536141Carcinoma, Renal Cell · United States, Australia, South Korea and more | 1 | Recruiting | Mar 2029 | 512 |
| NCT05117554Healthy Participants · Netherlands | 1 | Completed | Feb 17, 2023 | 70 |
How it is read
Names in the registry
- “Casdatifan”, 6 entries
- “casdatifan”, 2 entries
- “AB521”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Renal Cell, 3 studies
- Clear-cell metastatic renal cell carcinoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.